With Few New Clotting Cases, Johnson & Johnson Pause Could Be Lifted Soon
WASHINGTON Federal health officials are leaning toward lifting their recommended pause on the use of Johnson & Johnsons coronavirus vaccine after finding only a limited number of additional cases of a rare blood clotting disorder among recipients.
Instead, the Food and Drug Administration is considered likely to attach a warning to the vaccines label to inform health practitioners and the public about the exceedingly uncommon, but dangerous possible side effect.
Federal health officials are waiting to act until they hear from a committee of outside experts who advise the C.D.C. The committee is scheduled to meet on Friday to discuss whether to recommend lifting, extending or modifying the pause that was initiated on April 13.
We know that its not a good thing to leave the pause going for any longer than it absolutely has to go for, Dr. Peter Marks, the Food and Drug Administrations top vaccine regulator, said Thursday, adding that a protracted pause could contribute to greater vaccine hesitancy. Once, essentially, the adequate discussion has occurred, were prepared to move as quickly as we possibly can.
https://www.msn.com/en-us/health/medical/with-few-new-clotting-cases-johnson-and-johnson-pause-could-be-lifted-soon/ar-BB1fWNWS